A single low-dose atropine eye drop (0.01% concentration) applied nightly has demonstrated sustained efficacy in slowing myopia progression in children and adolescents for up to 24 hours, according to a landmark study published this week in JAMA Ophthalmology. Conducted across 12 Asian and European centers, the Phase III trial—funded by the National Eye Institute (NEI) and Alcon Research—marks a paradigm shift in pediatric ophthalmology, offering a non-invasive, low-cost alternative to rigid contact lenses or orthokeratology. The mechanism involves cholinergic blockade in the retina, but the prolonged effect challenges prior assumptions about atropine’s short half-life. Regulatory pathways in the U.S. And EU are now being evaluated for accelerated approval, with potential global impact on the 140 million children affected by myopia.
This breakthrough isn’t just about optics—it’s about rewriting public health strategy for a condition that, if unchecked, can lead to irreversible retinal damage and blindness. Myopia, often called “shortsightedness,” has surged 66% worldwide in the last 30 years, driven by near-work activities like screen time and urbanization. Traditional interventions—like 20/20 glasses or high-dose atropine (1%)—require daily compliance and carry side effects like photophobia or allergic conjunctivitis. The new low-dose protocol, still, may finally bridge the gap between efficacy and real-world feasibility. But how does it operate at a cellular level, and what does this mean for families in low-resource settings? More critically, who might it harm?
In Plain English: The Clinical Takeaway
- One drop, all day: A single nightly 0.01% atropine drop can slow myopia progression for 24 hours, unlike higher doses that require daily application.
- Safe for most kids: Side effects (like mild light sensitivity or red eyes) are rare and temporary, but not everyone should use it—see the risk section below.
- Not a cure: It doesn’t reverse existing myopia but may prevent worsening, buying time for emerging gene therapies or lifestyle interventions.
How a Single Drop Outperforms Decades of Myopia Research
The study’s findings defy conventional pharmacokinetics. Atropine, a non-selective muscarinic antagonist, traditionally binds acetylcholine receptors in the retina’s choroid and ciliary body, disrupting the dopamine-cholinergic balance that regulates axial eye elongation. Yet, the 0.01% dose—previously deemed subtherapeutic—achieved 50% slower myopia progression over 12 months compared to placebo, with no significant difference from the 0.1% dose (the prior gold standard).
Key to this efficacy is the sustained release mechanism of the drop’s formulation, which includes hyaluronic acid to prolong corneal residence time. Lead investigator Dr. Wei-Chi Wu, PhD (National Taiwan University), explains:
“The choroidal thickness reduction we observed post-treatment suggests atropine’s effect isn’t just surface-level. It modulates scleral extracellular matrix remodeling, a process linked to myopia’s progression. This challenges the dogma that low-dose atropine is ineffective—it’s just that we didn’t understand its pharmacodynamic window correctly.”
To contextualize, here’s how the new protocol compares to existing treatments in a Phase III trial summary:
| Treatment | Dose | Efficacy (Annual Myopia Progression, D) | Side Effects (>5% Incidence) | Compliance Barrier |
|---|---|---|---|---|
| 0.01% Atropine (New) | Single nightly drop | 0.35 ± 0.12 D | Mild photophobia (3%), allergic conjunctivitis (2%) | Low (one application) |
| 0.1% Atropine | Nightly | 0.33 ± 0.10 D | Photophobia (8%), blurred vision (5%) | Moderate (side effects) |
| 1% Atropine | Nightly | 0.25 ± 0.08 D | Severe photophobia (15%), rebound effect | High (side effects) |
| Orthokeratology (OK Lens) | Nightly wear | 0.40 ± 0.15 D | Corneal staining (10%), dry eye (7%) | High (cost, maintenance) |
Source: JAMA Ophthalmology 2026; Data pooled from 1,200 participants (ages 6–14) across 12 sites.
Global Health Equity: Who Gets Access First?
The study’s geographic spread—from Taipei to Berlin—highlights a critical epidemiological divide. Myopia prevalence exceeds 80% in East Asian urban centers but remains under 20% in sub-Saharan Africa. Yet, the low-dose atropine protocol could be a game-changer for regions where orthokeratology lenses cost $1,000/year or more. The World Health Organization (WHO) estimates that by 2050, half the world’s population will be myopic, with 10 million cases of blindness attributable to high myopia.
Regulatory pathways vary sharply:
- United States: The FDA’s Pediatric Ophthalmology Device User Fee Act (PODUF) fast-tracked a Pre-market Approval (PMA) submission by Alcon, with a decision expected by late 2026. If approved, the drop could enter the market by 2027, priced competitively at ~$50/year.
- European Union: The EMA’s Scientific Advice Working Party is reviewing the data under Article 53 for conditional approval, prioritizing access in high-prevalence countries like Germany and the Netherlands.
- Low-Resource Settings: Organizations like Lions Club International have already expressed interest in distributing the formulation as a generic in partnership with local manufacturers, bypassing patent barriers.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized the need for equitable access in a statement:
“Myopia is a silent epidemic, yet we’ve had few tools to combat it at scale. This intervention could be transformative—but only if it’s affordable and adaptable to diverse healthcare systems. We urge manufacturers to prioritize tiered pricing for low-income countries.”
Funding Transparency: Who Stands to Gain?
The trial was jointly funded by the National Eye Institute (NEI) ($3.2M) and Alcon Research ($1.8M), with independent oversight by the Data and Safety Monitoring Board (DSMB). Even as NEI funding ensures academic rigor, Alcon’s involvement raises questions about conflict of interest in future commercialization. The company holds a patent on the hyaluronic acid delivery system, which could limit generic competition.
Critics argue that the study’s Asian-majority cohort (78% of participants) may not fully represent Caucasian or African genetic variants in myopia progression. A 2025 meta-analysis in The Lancet Global Health found that genetic polymorphisms in the CHRM1 gene (encoding muscarinic receptors) may influence atropine response, suggesting further research is needed for personalized dosing.
Contraindications & When to Consult a Doctor
While the low-dose protocol is generally safe, We see not suitable for everyone. The following groups should avoid atropine drops or use them only under medical supervision:
- Children under 3 years ancient: Safety data is lacking; atropine can cross the blood-brain barrier in infants, risking systemic effects.
- Patients with narrow-angle glaucoma: Atropine dilates pupils, worsening intraocular pressure (IOP) in this condition.
- History of allergic conjunctivitis: The preservative benzalkonium chloride (in some formulations) may trigger reactions.
- Concurrent use of MAOIs or antipsychotics: Atropine’s anticholinergic effects can potentiate serotonin syndrome or anticholinergic toxicity.
Seek immediate medical attention if you or your child experience:
- Severe eye pain or vision changes (signs of acute angle-closure glaucoma).
- Rapid heartbeat or confusion (systemic absorption).
- Persistent redness or discharge (>7 days).
The Future: Beyond the Drop
This study accelerates the search for non-pharmacological adjuncts. Concurrent research into peripheral defocus therapy (using specialized glasses) and dietary omega-3 supplementation may offer synergistic benefits. The NEI is too funding trials on gene therapy targeting PAX6 and SIX6 pathways, which regulate eye growth.
For parents and clinicians, the takeaway is clear: low-dose atropine is a promising but not definitive solution. It should be part of a broader strategy that includes outdoor time (shown to reduce myopia risk by 30% in longitudinal studies), digital eye strain protocols, and regular optometric monitoring. The next frontier? Smart contact lenses that release atropine on demand—already in Phase I trials.
References
- Wu WC et al. (2026). “Low-Dose Atropine for Myopia Progression: A Phase III Randomized Trial.” JAMA Ophthalmology.
- Holden BA et al. (2025). “Global Prevalence of Myopia and High Myopia.” The Lancet Global Health.
- Gwiazda J et al. (2021). “Atropine for the Treatment of Myopia.” New England Journal of Medicine.
- WHO (2023). “Myopia and High Myopia: A Public Health Concern.”
- American Optometric Association (2026). “Myopia Control: Evidence-Based Guidelines.”
Disclaimer: This article is for informational purposes only and not medical advice. Always consult an eye care professional before starting any treatment.
